Lupin divests US women’s health specialty business to Evofem
Lupin’s US Commercial Women’s Health Specialty Business is primarily focused on commercialising Solosec (secnidazole), an antibiotic medication approved for the treatment of bacterial vaginosis (BV) in women
![](https://www.worldpharmaceuticals.net/wp-content/uploads/sites/12/2024/07/New-Project-51-1024x576.webp)
Effects of interstate armed conflicts on the pharmaceutical industry
Unveiling the impact of misinformation and disinformation in the pharmaceutical industry
The ripple effects of inflation on the pharmaceutical industry
Extreme weather events: The implications for the pharmaceutical industry